Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HP802-247 in Dystrophic Epidermolysis Bullosa
NCT01528306Phase 2Withdrawn
- Sponsor
- Healthpoint Biotherapeutics
- Start
- Mar 2012
- Primary completion
- Mar 2013
- Modality
- Implantable Devices, Implantable Hydrogels, Cell Therapies
01
Overview
A Phase 2 trial of HP-802-247 in dystrophic epidermolysis bullosa (DEB), sponsored by Healthpoint Biotherapeutics. Planned start Mar 2012; status: withdrawn.
02
Drugs
HP-802-247
03
Conditions
dystrophic epidermolysis bullosa (DEB)
Beyond the preview
Go deeper on NCT01528306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01528306.